The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global G-CSF and G-CSF Biosimilars Market Research Report 2025

Global G-CSF and G-CSF Biosimilars Market Research Report 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1903575

No of Pages : 94

Ask Your Query
Synopsis
G-CSF, which is also known as filgrastim, is a growth factor used to aid the recovery of bone marrow after chemotherapy treatment for cancer, especially in patients with neutropenia (low white blood cell count in the blood), which causes reduced resistance to infections. It can also be used to stimulate mobilization of haematopoietic stem cells for collection and transplantation.
The global G-CSF and G-CSF Biosimilars market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for G-CSF and G-CSF Biosimilars, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding G-CSF and G-CSF Biosimilars.
Report Scope
The G-CSF and G-CSF Biosimilars market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global G-CSF and G-CSF Biosimilars market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the G-CSF and G-CSF Biosimilars manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
Novartis
Roche
Merck & Co.
Sanofi
Johnson & Johnson
Gilead Science
GlaxoSmithKline
AbbVie
Amgen
AstraZeneca
Bayer
Segment by Type
Blood Disorders
Oncology Diseases
Chronic And Autoimmune Diseases
Growth Hormone Deficiencies
Segment by Application
Human Growth Hormone
Erythropoietin
Monoclonal Antibodies
Insulin
Interferon
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of G-CSF and G-CSF Biosimilars manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of G-CSF and G-CSF Biosimilars in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index
1 G-CSF and G-CSF Biosimilars Market Overview
1.1 Product Overview and Scope of G-CSF and G-CSF Biosimilars
1.2 G-CSF and G-CSF Biosimilars Segment by Type
1.2.1 Global G-CSF and G-CSF Biosimilars Market Value Comparison by Type (2024-2030)
1.2.2 Blood Disorders
1.2.3 Oncology Diseases
1.2.4 Chronic And Autoimmune Diseases
1.2.5 Growth Hormone Deficiencies
1.3 G-CSF and G-CSF Biosimilars Segment by Application
1.3.1 Global G-CSF and G-CSF Biosimilars Market Value by Application: (2024-2030)
1.3.2 Human Growth Hormone
1.3.3 Erythropoietin
1.3.4 Monoclonal Antibodies
1.3.5 Insulin
1.3.6 Interferon
1.4 Global G-CSF and G-CSF Biosimilars Market Size Estimates and Forecasts
1.4.1 Global G-CSF and G-CSF Biosimilars Revenue 2019-2030
1.4.2 Global G-CSF and G-CSF Biosimilars Sales 2019-2030
1.4.3 Global G-CSF and G-CSF Biosimilars Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 G-CSF and G-CSF Biosimilars Market Competition by Manufacturers
2.1 Global G-CSF and G-CSF Biosimilars Sales Market Share by Manufacturers (2019-2024)
2.2 Global G-CSF and G-CSF Biosimilars Revenue Market Share by Manufacturers (2019-2024)
2.3 Global G-CSF and G-CSF Biosimilars Average Price by Manufacturers (2019-2024)
2.4 Global G-CSF and G-CSF Biosimilars Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of G-CSF and G-CSF Biosimilars, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of G-CSF and G-CSF Biosimilars, Product Type & Application
2.7 G-CSF and G-CSF Biosimilars Market Competitive Situation and Trends
2.7.1 G-CSF and G-CSF Biosimilars Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest G-CSF and G-CSF Biosimilars Players Market Share by Revenue
2.7.3 Global G-CSF and G-CSF Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 G-CSF and G-CSF Biosimilars Retrospective Market Scenario by Region
3.1 Global G-CSF and G-CSF Biosimilars Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global G-CSF and G-CSF Biosimilars Global G-CSF and G-CSF Biosimilars Sales by Region: 2019-2030
3.2.1 Global G-CSF and G-CSF Biosimilars Sales by Region: 2019-2024
3.2.2 Global G-CSF and G-CSF Biosimilars Sales by Region: 2025-2030
3.3 Global G-CSF and G-CSF Biosimilars Global G-CSF and G-CSF Biosimilars Revenue by Region: 2019-2030
3.3.1 Global G-CSF and G-CSF Biosimilars Revenue by Region: 2019-2024
3.3.2 Global G-CSF and G-CSF Biosimilars Revenue by Region: 2025-2030
3.4 North America G-CSF and G-CSF Biosimilars Market Facts & Figures by Country
3.4.1 North America G-CSF and G-CSF Biosimilars Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America G-CSF and G-CSF Biosimilars Sales by Country (2019-2030)
3.4.3 North America G-CSF and G-CSF Biosimilars Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe G-CSF and G-CSF Biosimilars Market Facts & Figures by Country
3.5.1 Europe G-CSF and G-CSF Biosimilars Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe G-CSF and G-CSF Biosimilars Sales by Country (2019-2030)
3.5.3 Europe G-CSF and G-CSF Biosimilars Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific G-CSF and G-CSF Biosimilars Market Facts & Figures by Country
3.6.1 Asia Pacific G-CSF and G-CSF Biosimilars Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific G-CSF and G-CSF Biosimilars Sales by Country (2019-2030)
3.6.3 Asia Pacific G-CSF and G-CSF Biosimilars Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America G-CSF and G-CSF Biosimilars Market Facts & Figures by Country
3.7.1 Latin America G-CSF and G-CSF Biosimilars Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America G-CSF and G-CSF Biosimilars Sales by Country (2019-2030)
3.7.3 Latin America G-CSF and G-CSF Biosimilars Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa G-CSF and G-CSF Biosimilars Market Facts & Figures by Country
3.8.1 Middle East and Africa G-CSF and G-CSF Biosimilars Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa G-CSF and G-CSF Biosimilars Sales by Country (2019-2030)
3.8.3 Middle East and Africa G-CSF and G-CSF Biosimilars Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global G-CSF and G-CSF Biosimilars Sales by Type (2019-2030)
4.1.1 Global G-CSF and G-CSF Biosimilars Sales by Type (2019-2024)
4.1.2 Global G-CSF and G-CSF Biosimilars Sales by Type (2025-2030)
4.1.3 Global G-CSF and G-CSF Biosimilars Sales Market Share by Type (2019-2030)
4.2 Global G-CSF and G-CSF Biosimilars Revenue by Type (2019-2030)
4.2.1 Global G-CSF and G-CSF Biosimilars Revenue by Type (2019-2024)
4.2.2 Global G-CSF and G-CSF Biosimilars Revenue by Type (2025-2030)
4.2.3 Global G-CSF and G-CSF Biosimilars Revenue Market Share by Type (2019-2030)
4.3 Global G-CSF and G-CSF Biosimilars Price by Type (2019-2030)
5 Segment by Application
5.1 Global G-CSF and G-CSF Biosimilars Sales by Application (2019-2030)
5.1.1 Global G-CSF and G-CSF Biosimilars Sales by Application (2019-2024)
5.1.2 Global G-CSF and G-CSF Biosimilars Sales by Application (2025-2030)
5.1.3 Global G-CSF and G-CSF Biosimilars Sales Market Share by Application (2019-2030)
5.2 Global G-CSF and G-CSF Biosimilars Revenue by Application (2019-2030)
5.2.1 Global G-CSF and G-CSF Biosimilars Revenue by Application (2019-2024)
5.2.2 Global G-CSF and G-CSF Biosimilars Revenue by Application (2025-2030)
5.2.3 Global G-CSF and G-CSF Biosimilars Revenue Market Share by Application (2019-2030)
5.3 Global G-CSF and G-CSF Biosimilars Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Corporation Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer G-CSF and G-CSF Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Pfizer G-CSF and G-CSF Biosimilars Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 Novartis
6.2.1 Novartis Corporation Information
6.2.2 Novartis Description and Business Overview
6.2.3 Novartis G-CSF and G-CSF Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Novartis G-CSF and G-CSF Biosimilars Product Portfolio
6.2.5 Novartis Recent Developments/Updates
6.3 Roche
6.3.1 Roche Corporation Information
6.3.2 Roche Description and Business Overview
6.3.3 Roche G-CSF and G-CSF Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Roche G-CSF and G-CSF Biosimilars Product Portfolio
6.3.5 Roche Recent Developments/Updates
6.4 Merck & Co.
6.4.1 Merck & Co. Corporation Information
6.4.2 Merck & Co. Description and Business Overview
6.4.3 Merck & Co. G-CSF and G-CSF Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Merck & Co. G-CSF and G-CSF Biosimilars Product Portfolio
6.4.5 Merck & Co. Recent Developments/Updates
6.5 Sanofi
6.5.1 Sanofi Corporation Information
6.5.2 Sanofi Description and Business Overview
6.5.3 Sanofi G-CSF and G-CSF Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Sanofi G-CSF and G-CSF Biosimilars Product Portfolio
6.5.5 Sanofi Recent Developments/Updates
6.6 Johnson & Johnson
6.6.1 Johnson & Johnson Corporation Information
6.6.2 Johnson & Johnson Description and Business Overview
6.6.3 Johnson & Johnson G-CSF and G-CSF Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Johnson & Johnson G-CSF and G-CSF Biosimilars Product Portfolio
6.6.5 Johnson & Johnson Recent Developments/Updates
6.7 Gilead Science
6.6.1 Gilead Science Corporation Information
6.6.2 Gilead Science Description and Business Overview
6.6.3 Gilead Science G-CSF and G-CSF Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Gilead Science G-CSF and G-CSF Biosimilars Product Portfolio
6.7.5 Gilead Science Recent Developments/Updates
6.8 GlaxoSmithKline
6.8.1 GlaxoSmithKline Corporation Information
6.8.2 GlaxoSmithKline Description and Business Overview
6.8.3 GlaxoSmithKline G-CSF and G-CSF Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.8.4 GlaxoSmithKline G-CSF and G-CSF Biosimilars Product Portfolio
6.8.5 GlaxoSmithKline Recent Developments/Updates
6.9 AbbVie
6.9.1 AbbVie Corporation Information
6.9.2 AbbVie Description and Business Overview
6.9.3 AbbVie G-CSF and G-CSF Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.9.4 AbbVie G-CSF and G-CSF Biosimilars Product Portfolio
6.9.5 AbbVie Recent Developments/Updates
6.10 Amgen
6.10.1 Amgen Corporation Information
6.10.2 Amgen Description and Business Overview
6.10.3 Amgen G-CSF and G-CSF Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Amgen G-CSF and G-CSF Biosimilars Product Portfolio
6.10.5 Amgen Recent Developments/Updates
6.11 AstraZeneca
6.11.1 AstraZeneca Corporation Information
6.11.2 AstraZeneca G-CSF and G-CSF Biosimilars Description and Business Overview
6.11.3 AstraZeneca G-CSF and G-CSF Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.11.4 AstraZeneca G-CSF and G-CSF Biosimilars Product Portfolio
6.11.5 AstraZeneca Recent Developments/Updates
6.12 Bayer
6.12.1 Bayer Corporation Information
6.12.2 Bayer G-CSF and G-CSF Biosimilars Description and Business Overview
6.12.3 Bayer G-CSF and G-CSF Biosimilars Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Bayer G-CSF and G-CSF Biosimilars Product Portfolio
6.12.5 Bayer Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 G-CSF and G-CSF Biosimilars Industry Chain Analysis
7.2 G-CSF and G-CSF Biosimilars Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 G-CSF and G-CSF Biosimilars Production Mode & Process
7.4 G-CSF and G-CSF Biosimilars Sales and Marketing
7.4.1 G-CSF and G-CSF Biosimilars Sales Channels
7.4.2 G-CSF and G-CSF Biosimilars Distributors
7.5 G-CSF and G-CSF Biosimilars Customers
8 G-CSF and G-CSF Biosimilars Market Dynamics
8.1 G-CSF and G-CSF Biosimilars Industry Trends
8.2 G-CSF and G-CSF Biosimilars Market Drivers
8.3 G-CSF and G-CSF Biosimilars Market Challenges
8.4 G-CSF and G-CSF Biosimilars Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock